Insulet Names Aiman Abdel-Malek, Ph.D. Senior Vice President of Advanced Technology and Engineering

BILLERICA, Mass., March 16, 2016 /PRNewswire/ -- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its OmniPod^® Insulin Management System (OmniPod System), today announced the appointment of Aiman Abdel-Malek, Ph.D. as Senior Vice President of Advanced Technology and Engineering, effective March 28, 2016. Dr. Abdel-Malek will be responsible for overseeing the Company's global Research and Development and Engineering functions. He will report directly to Patrick Sullivan, President and Chief Executive Officer.

Dr. Abdel-Malek brings nearly 30 years of healthcare and technology focused engineering and business development experience. Most recently, he served as President of Frictionless Life Analytics, Inc., a business development and technology advisory and consultancy firm, which enables the growth of start-up ventures focused on Internet of Things (IoT) platforms and solutions. Previously, he served as Vice President of Engineering of the Mobile Healthcare division of Qualcomm where he led a group in creating cloud-based solutions for disease management. Prior to Qualcomm, he spent 25 years at General Electric, serving in various roles of increasing responsibility, including General Manager of Global Services Technology for General Electric Healthcare Services. Dr. Abdel-Malek holds a Ph.D. in Biomedical Engineering from the University of Southern California, Los Angeles, and a B.Sc. in Systems and Biomedical Engineering from the University of Cairo in Egypt.

"Aiman's proven record of leading teams in technological advancements will be a significant asset for Insulet," said Patrick Sullivan, President and Chief Executive Officer. "Our unique and differentiated product offerings are based on leading technology platforms and engineering designs. Aiman will provide the technical leadership necessary to leverage the most advanced technologies and development processes for Insulet. We look forward to drawing on Aiman's expertise in meeting the expanding needs of patients and physicians and increasing value for our shareholders."

Dr. Aiman Abdel-Malek stated, "Insulet is transforming healthcare solutions for both insulin and non-insulin drug delivery and I am excited to put my skills and background to use in advancing the Company's technology and market position. I am thrilled to join the strong senior leadership team and a truly innovative healthcare technology company."

About Insulet Corporation:

Insulet Corporation (NASDAQ: PODD) is an innovative medical device company dedicated to making the lives of people with diabetes easier. Through its OmniPod Insulin Management System, Insulet seeks to expand the use of insulin pump therapy among people with insulin-dependent diabetes. The OmniPod is a revolutionary and easy-to-use tubeless insulin pump that features just two parts and a fully-automated cannula insertion. Insulet's Delivery Systems business also partners with global pharmaceutical and biotechnology companies to tailor the OmniPod technology platform for the delivery of subcutaneous drugs across multiple therapeutic areas. To read inspiring stories of people with diabetes living their lives to the fullest with OmniPod, please visit our customer blog, Suite D: http://suited.myomnipod.com. Founded in 2000, Insulet Corporation is based in Billerica, Massachusetts. For more information, please visit: http://www.myomnipod.com.

Forward-Looking Statement:

This press release may contain forward-looking statements concerning Insulet's expectations, anticipations, intentions, beliefs or strategies regarding the future. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects on Insulet. There can be no assurance that future developments affecting Insulet will be those that it has anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond its control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements, and other risks and uncertainties described in its Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission on February 29, 2016 in the section entitled "Risk Factors," and in its other filings from time to time with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of its assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Insulet undertakes no obligation to publicly update or revise any forward-looking statements.

Investor Relations and Media Contact:

Deborah R. Gordon 
Vice President, Investor Relations and Corporate Communications 
(978) 600-7717 
[email protected]

SOURCE Insulet Corporation

Related Links

http://www.myomnipod.com